Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients

被引:30
|
作者
Viscoli, C
Paesmans, M
Sanz, M
Castagnola, E
Klastersky, J
Martino, P
Glauser, M
机构
[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Univ Genoa, Genoa, Italy
[3] G Gaslini Inst Children, Genoa, Italy
[4] Univ Roma La Sapienza, Rome, Italy
[5] Inst Jules Bordet, B-1000 Brussels, Belgium
[6] Univ Valencia, La Fe Univ Hosp, Valencia, Spain
[7] CHU Vaudois, CH-1011 Lausanne, Switzerland
关键词
D O I
10.1086/320514
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P = .0001). In a multivariate model without including antifungal prophylaxis, factors associated with bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included, the adjustment quality of the model improved slightly (P = .05), with an odds ratio of 1.19 (95% confidence interval [CI], 0.92- 1.55) for patients receiving nonabsorbable and 1.42 (95% CI, 1.07- 1.88) for those who were receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.
引用
收藏
页码:1532 / 1537
页数:6
相关论文
共 50 条
  • [1] Antifungal prophylaxis and the rate of bacteremia among neutropenic patients
    Viscoli, C
    Paesmans, M
    CLINICAL INFECTIOUS DISEASES, 2002, 34 (02) : 289 - 291
  • [2] Lactobacillus bacteremia in febrile neutropenic patients in a cancer hospital
    Cooper, CD
    Vincent, A
    Greene, JN
    Sandin, RL
    Cobian, L
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (05) : 1247 - 1248
  • [3] Antifungal prophylaxis in neutropenic patients
    Boogaerts, MA
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1996, 6 (03) : 149 - 154
  • [4] RISK FACTORS FOR BACTEREMIA IN FEBRILE NEUTROPENIC EPISODES IN PATIENTS WITH COLORECTAL CANCER
    Sfiris, I.
    Heras, P.
    Hatzopoulos, A.
    Kritikos, K.
    Heras, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 394 - 394
  • [5] Association between cytokine concentration kinetics and prolonged fever in febrile neutropenic children with bacteremia
    Kim, Seong Koo
    Han, Seung Beom
    Kang, Jin Han
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2022, 36
  • [6] Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients
    Nuray Buyukberber
    Süleyman Buyukberber
    Alper Sevinc
    Celalettin Camci
    Medical Oncology, 2009, 26 : 55 - 61
  • [7] Pharmacokinetics and pharmacodynamics of meropenern in febrile neutropenic patients with bacteremia
    Ariano, RE
    Nyhlén, A
    Donnelly, JP
    Sitar, DS
    Harding, GKM
    Zelenitsky, SA
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) : 32 - 38
  • [8] Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients
    Buyukberber, Nuray
    Buyukberber, Suleyman
    Sevinc, Alper
    Camci, Celalettin
    MEDICAL ONCOLOGY, 2009, 26 (01) : 55 - 61
  • [9] Antifungal prophylaxis in neutropenic cancer patients and allogeneic bone marrow transplantation
    Blau, IW
    Fauser, AA
    MYCOSES, 1996, 39 : 81 - 86
  • [10] Pharmacoeconomic evaluation of antifungal prophylaxis in neutropenic patients
    Ruepp, K.
    Stollenwerk, B.
    Brunner, H.
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 296 : 162 - 162